Hints and tips:
...two listed companies on Germany’s benchmark Dax index are rare — among the most recent examples are Dresdner Bank’s ill-fated takeover by Allianz in 2001 and Bayer’s acquisition of pharmaceuticals group Schering...
...Mr Hudson, 51, has spent his 28-year career with pharma companies including Schering-Plough, AstraZeneca and Novartis, in the US, Japan and Europe....
UK regulators are under pressure from Big Pharma as well as patients
...Then in 2006 Bayer broke its own record by splashing out €17bn to buy Schering, a German healthcare company....
...Mr Campbell said: “The trajectory for Bayer over the last five to seven years has definitely been towards more healthcare and less chemicals, buying Algeta, buying Schering and selling Lanxess.”...
...It is Bayer’s second-largest acquisition after buying Schering for $17bn in 2006....
...latest in a series of Bayer acquisitions that have aligned the company around life sciences, following the $2.9bn takeover last year of Algeta, the Norwegian cancer drug company, and $17bn purchase of Schering...
...was the norm at the start of this century, from the merger that created GlaxoSmithKline in 2000 and the $67bn purchase of Aventis by Sanofi in 2004, to Pfizer’s $68bn paid for Wyeth, Merck’s $41bn for Schering-Plough...
...In the previous decade, companies tended to fill holes in sales through large acquisitions, such as Merck’s $41bn purchase of Schering-Plough, and Pfizer’s of Wyeth in 2009 for $68bn....
...In pharmaceuticals, Fred Hassan received $189m when Schering Plough was bought by Merck, and Hank McKinnell got $188m when he left Pfizer, despite an investor campaign under the slogan “give it back, Hank...
...Mr Wijers started by spinning off Organon to Schering Plough in 2007....
...The Genentech deal, combined with the “megamergers” in the same year of Pfizer’s $68bn purchase of Wyeth and Merck’s of Schering-Plough for $41bn, was a recent high water mark in dealmaking in the healthcare...
...buy-backs and dividend increases as well as unveiling plans to appoint to its board Jean-Pierre Garnier, the former head of GlaxoSmithKline, and Robert Bertolini, the former chief financial officer of Schering-Plough...
...pharmaceutical companies, which had jointly run Merial since 1997, and announced their intention in March last year to recombine their assets to include products acquired by Merck after its acquisition of Schering-Plough...
...Afterwards Merck, which acquired the company when it took over Schering-Plough, shrank its operations drastically....
...Mr Clark, who took charge in 2005, adopted a relatively low public profile while overseeing changes including the $49bn takeover last year of Schering-Plough; an expansion of partnerships and alliances with...
...If the Schering results are included in the 2009 numbers, Merck sales fell to $11.1bn from $11.5bn in the same period last year....
...In the US, Merck has announced plans to cut 15 per cent of the workforce, or 15,000 jobs, by 2012 in restructuring after buying Schering-Plough....
...In the good old days of Deutschland AG, the banks would have rallied to Hochtief’s cause....
...In particular the names of messrs Siemens Schuckert, messrs Bayer and messrs Schering & Co have come to notice in this connection.”...
Prospect of greater burden in any further rescue packages
...The deal will combine the French drugmaker’s Merial unit and Merck’s Intervet/Schering Plough division. Sanofi shares added 0.8 per cent to €56.17....
...Last year, it helped fill holes in its own pipeline with the purchase of Schering-Plough....
...expenditure and closed some disease-research units in the past few months, partly to reduce duplication following a series of large-scale acquisitions such as Pfizer’s takeover of Wyeth and Merck’s of Schering-Plough...
International Edition